World leaders want to end Alzheimer’s by 2015 as new clinical trial shows glimmer of hope

The discovery of an antibody therapy capable of reducing and slowing down the formation of plaques or beta-amyloid cluster, was observed by a US biotechnology company Biogen.
This gave rise to a milestone moments thanks to the discovery by Biogen presented at the Alzheimer’s Association International Conference in Chicago.